In this edition, FDA places hold on cell therapy trial after patient death, selpercatinib delivers superior outcomes and more. Read the full coverage here:

FDA places hold on trial of cell therapy for lung cancer after patient death

Selpercatinib delivers superior outcomes, may ‘reduce the burden of NSCLC’

First-line immunotherapy benefits patients of all races with NSCLC equally

Never-smoker lung cancer survivors require targeted surveillance

Cemiplimab plus chemotherapy improves outcomes in metastatic NSCLC

References:

Baramidze A, et al. Abstract 1495P. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.

Choi E, et al. JAMA Netw. Open. 2023;doi:10.1001/jamanetworkopen.2023.43278.

Lee M, et al. J. Natl Compr Canc Netw. 2023;doi:10.6004/jnccn.2023.7064

Press Release

Zhou C, et al. N Engl J Med. 2023;doi:10.1056.NEJMoa2309457.